PT2435039E - Combinação de uma fonte de leucina e uma fonte de ácido gordo insaturado omega-3 para uso no tratamento de hipercalcemia - Google Patents

Combinação de uma fonte de leucina e uma fonte de ácido gordo insaturado omega-3 para uso no tratamento de hipercalcemia Download PDF

Info

Publication number
PT2435039E
PT2435039E PT107266165T PT10726616T PT2435039E PT 2435039 E PT2435039 E PT 2435039E PT 107266165 T PT107266165 T PT 107266165T PT 10726616 T PT10726616 T PT 10726616T PT 2435039 E PT2435039 E PT 2435039E
Authority
PT
Portugal
Prior art keywords
source
hypercalcaemia
omega
treatment
combination
Prior art date
Application number
PT107266165T
Other languages
English (en)
Inventor
Klaske Van Norren
Joyce Faber
Adrianus Lambertus Bertholdus Van Helvoort
Robert Johan Joseph Hageman
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2435039(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of PT2435039E publication Critical patent/PT2435039E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT107266165T 2009-05-27 2010-05-27 Combinação de uma fonte de leucina e uma fonte de ácido gordo insaturado omega-3 para uso no tratamento de hipercalcemia PT2435039E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2009/050297 WO2010137944A1 (en) 2009-05-27 2009-05-27 Treatment of hypercalcaemia

Publications (1)

Publication Number Publication Date
PT2435039E true PT2435039E (pt) 2016-01-08

Family

ID=41397536

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107266165T PT2435039E (pt) 2009-05-27 2010-05-27 Combinação de uma fonte de leucina e uma fonte de ácido gordo insaturado omega-3 para uso no tratamento de hipercalcemia

Country Status (12)

Country Link
US (2) US20120122785A1 (pt)
EP (2) EP2987485B1 (pt)
CN (2) CN104257646A (pt)
BR (1) BRPI1012077B8 (pt)
DK (1) DK2435039T4 (pt)
ES (1) ES2555860T5 (pt)
HU (1) HUE028295T2 (pt)
MX (1) MX2011012573A (pt)
PL (1) PL2435039T5 (pt)
PT (1) PT2435039E (pt)
RU (1) RU2555359C2 (pt)
WO (2) WO2010137944A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012141575A1 (en) 2011-04-14 2012-10-18 N.V.Nutricia Combination of epa, dpa and/or dha with a chemotherapeutic agent
WO2012143405A1 (en) * 2011-04-18 2012-10-26 Nestec S.A. Nutritional compositions having alpha-hica and alpha-ketoglutarate
WO2015002527A1 (en) 2013-07-05 2015-01-08 N.V. Nutricia Amino acid composition for use in the treatment of a pdd
US9616292B2 (en) * 2015-01-09 2017-04-11 Nolan Orfield Exercise tracker
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05178758A (ja) * 1991-03-22 1993-07-20 Suntory Ltd トリペプチドを有効成分とする骨疾患の予防および治療剤
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
JPH05140063A (ja) * 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US20070037777A1 (en) * 2005-08-12 2007-02-15 Immunopath Profile, Inc. Lipid-containing compositions and methods of using them
GB0003310D0 (en) 2000-02-15 2000-04-05 Univ Sheffield Bone formation
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20040171692A1 (en) * 2003-02-28 2004-09-02 Scutt Andrew Modulation of bone formation
US20060159746A1 (en) 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
ATE433674T1 (de) * 2003-06-23 2009-07-15 Nestec Sa Säuglingsnährpräparat oder folgemilch
JP4702678B2 (ja) * 2004-06-07 2011-06-15 環境創研株式会社 競走馬用飼料添加材
BRPI0513447A (pt) † 2004-07-28 2008-06-10 Abbott Lab composições nutritivas e métodos para o tratamento ou prevenção de osteoporose
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
GB0624879D0 (en) * 2006-12-14 2007-01-24 Shs Int Ltd Treatment of pervasive development disorders
US20080171791A1 (en) * 2007-01-11 2008-07-17 Mdr Fitness Corp. Compositions and Method for Losing Weight
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
WO2008147228A1 (en) * 2007-05-31 2008-12-04 Fonterra Corporate Research And Development Limited Treatment or prevention of bone conditions
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
EP2025248A1 (en) * 2007-07-31 2009-02-18 Fresenius Kabi Deutschland GmbH Cachexia prevention supplement
WO2010002242A1 (en) * 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
CN101314031A (zh) * 2008-07-14 2008-12-03 王冰 一种改善骨营养的制剂

Also Published As

Publication number Publication date
HUE028295T2 (en) 2016-12-28
RU2555359C2 (ru) 2015-07-10
BRPI1012077B8 (pt) 2022-09-20
DK2435039T3 (en) 2015-12-21
EP2435039A2 (en) 2012-04-04
ES2555860T3 (es) 2016-01-11
EP2987485A1 (en) 2016-02-24
BRPI1012077A2 (pt) 2018-03-20
WO2010137944A1 (en) 2010-12-02
WO2010137979A2 (en) 2010-12-02
DK2435039T4 (da) 2019-05-06
WO2010137979A3 (en) 2011-04-14
CN104257646A (zh) 2015-01-07
EP2435039B2 (en) 2019-02-27
EP2987485B1 (en) 2020-02-26
CN102458390B (zh) 2014-10-29
EP2435039B1 (en) 2015-09-09
US9867796B2 (en) 2018-01-16
PL2435039T5 (pl) 2019-09-30
ES2555860T5 (es) 2019-07-12
RU2011152873A (ru) 2013-07-10
US20120122785A1 (en) 2012-05-17
MX2011012573A (es) 2011-12-14
BRPI1012077B1 (pt) 2021-05-18
WO2010137979A8 (en) 2011-11-17
PL2435039T3 (pl) 2016-02-29
US20150018277A1 (en) 2015-01-15
CN102458390A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
HK1226307A1 (zh) 用於治療高甘油三酯血症的二十碳五烯酸乙酯
HK1232207A1 (zh) 多不飽和脂肪酸的衍生物作為藥物的用途
IL228516A (en) A compound for oral administration containing an omega-3 fatty acid ester and rosovastatin
EP2521447A4 (en) FATTY FATTY ACID DERIVATIVES AND USES THEREOF
HK1198544A1 (en) Microbial oils enriched in polyunsaturated fatty acids
DK2424520T3 (da) Anvendelse af flerumættede fedtsyrer til behandling af hudinflammation
PL2408426T3 (pl) Kompozycje dooczne na bazie wielonienasyconych kwasów tłuszczowych omega-3 i omega-6
EP2459189A4 (en) FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
EP2440637A4 (en) BIOLUBRICANT ESTERS FROM UNSATURATED FATTY ACID ALCOHOLS
EP2782896A4 (en) PALM OIL ENHANCED WITH UNSATURATED FATTY ACIDS
PT2435039E (pt) Combinação de uma fonte de leucina e uma fonte de ácido gordo insaturado omega-3 para uso no tratamento de hipercalcemia
EP2619298A4 (en) METHOD FOR CONCENTRATING OMEGA 3 FATTY ACIDS
IL231374A (en) Use of epa and dha to treat eye disease
IL218460A0 (en) Omega-3 fatty acid enriched shortenings and nut butters
HUE038592T2 (hu) Telítetlen zsírsavak és ezek származékai ózonizálása
PT2842555T (pt) Derivados-alfa de ácidos gordos cis-monoinsaturados para uso como medicamentos no tratamento de diabetes
GB201304550D0 (en) Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof
EP2706847A4 (en) COUPLERS FOR MEDIUM CHAIN FATTY ACIDS AND DISINFECTANT COMPOSITIONS
HK1210058A1 (en) Esters of short chains fatty acids for use in the treatment of immunogenic disorders
EP3567025B8 (en) Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
ZA201503808B (en) Use of a dha ester for prophylactic and/or curative treatment of drepanocytosis
TH112765B (th) การผลิตของกรดที่ไม่อิ่มตัวแบบเอธิลีน และเอสเทอร์ของสารนั้น
GB201104653D0 (en) Improvements in the manufacture of fatty acids
GB201001914D0 (en) CCL 17 Inhibitors for use in T helper cell-driven diseases
AU2011903165A0 (en) Docosahexaenoic acid (DHA)-containing compositions and uses thereof